Multiple Analyses Evaluating Celgene's ABRAXANE in Non-Small Cell Lung Cancer Presented at ASCO

Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) announced Saturday results from multiple presentations evaluating ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with carboplatin in patients with advanced non-small cell lung cancer during the 48th American Society of Clinical Oncology Annual Meeting in Chicago, IL.

The two reports presented data from retrospective analyses of CA-031, the phase III, multi-center, randomized study where patients received either nab-paclitaxel (100mg/m2) weekly plus carboplatin (AUC=6) every three weeks (n=521) or paclitaxel (200mg/m2) every three weeks plus carboplatin (AUC=6) (n=531) as first-line therapy for advanced non-small cell lung cancer.

Based on the data from CA-031, Celgene submitted an sNDA for ABRAXANE for the first-line treatment of patients with advanced non-small cell lung cancer with the U.S. Food and Drug Administration in December 2011. The current PDUFA date for the submission is Oct. 12, 2012.

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.